Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and Wegovy develop complications with their eyesight, highlighting that we ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

The digital health unicorn sells its chronic condition management and musculoskeletal programs to employers and health plans ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

If that person loses 20 kilograms (44 pounds) in one year while taking a GLP-1R agonist — which is not unreasonable while ...

The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...